Dr. Adelstein on Adjuvant Therapy for Oral Cancer

March 8, 2016
David Adelstein, MD

David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

Chemotherapy is a preferred treatment option for patients with high-risk disease, Adelstein explains. Evidence suggests that the use of high-dose cisplatin benefits select patients in terms of locoregional control and survival. However, there is less evidence showing that weekly treatment with cisplatin is as effective.

No data suggest that carboplatin, cetuximab, or taxane-based therapies in the adjuvant setting have a role in these patients. Radiation therapy has also shown to be a reasonable approach in patients who are unable to tolerate cisplatin.

<<<

View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium

x